论文部分内容阅读
目的探讨自体细胞因子诱导的杀伤(CIK)细胞过继免疫疗法联合TP方案(紫杉醇和顺铂)化疗治疗晚期非小细胞肺癌的临床疗效及毒副作用。方法收集我科57例晚期非小细胞肺癌患者随机分成2组,治疗组(25例)给予CIK细胞过继免疫治疗联合TP化疗;对照组(32例)行单纯TP化疗。随访观察患者接受治疗后其近远期疗效,同时记录患者的生存期。结果CIK细胞回输联合TP方案化疗临床受益率达92%,生存质量的卡氏评分提高率为84%,2年生存率达到48.0%,相较于单纯TP方案化疗有明显统计学意义。结论 CIK细胞过继免疫治疗联合TP化疗具有协同作用,治疗晚期非小细胞肺癌具有肯定的近期疗效并可改善其预后,延长了患者的生存期,且无明显毒副作用。
Objective To investigate the clinical efficacy and side effects of adoptive immunotherapy with cytokine-induced killer (CIK) cells combined with TP regimen (paclitaxel and cisplatin) in the treatment of advanced non-small cell lung cancer. Methods Fifty-seven patients with advanced non-small cell lung cancer (NSCLC) were randomly divided into two groups. The treatment group (25 cases) received CIK cell adoptive immunotherapy combined with TP chemotherapy. The control group (32 cases) received simple TP chemotherapy. Follow-up observation of patients receiving short-term and long-term efficacy after treatment, while recording the survival of patients. Results The clinical benefit rate of CIK cells combined with TP regimen was 92%. The improvement rate of Qoiety score of life quality was 84% and the 2-year survival rate was 48.0%, which was significantly different from that of TP alone chemotherapy. Conclusions CIK cell adoptive immunotherapy combined with TP chemotherapy has a synergistic effect. The treatment of advanced non-small cell lung cancer has certain short-term curative effect and can improve its prognosis, prolonging the survival of patients with no obvious side effects.